What is the role of sentinel lymph‑node (SLN) mapping in endometrial cancer based on current evidence?

Sentinel Lymph Node Mapping in Endometrial Cancer

Sentinel lymph node (SLN) mapping should be considered the standard approach for lymph node staging in endometrial cancer, replacing systematic lymphadenectomy in most clinical scenarios, with indocyanine green (ICG) as the preferred tracer. 1, 2

Evidence-Based Recommendations by Risk Category

Low-Risk Disease (FIGO IA G1-G2 Endometrioid)

• Lymph node evaluation can be omitted entirely as the risk of nodal metastasis is <5% 1
• If staging is performed, SLN mapping is acceptable 1

Intermediate and High-Intermediate Risk Disease

• SLN mapping is the preferred staging method 1, 2
• The FIRES trial (n=5,385) demonstrated 86% successful mapping with 97.2% sensitivity and 99.6% negative predictive value 2
• This approach safely identifies nodal disease without the morbidity of complete lymphadenectomy

High-Risk Disease (Grade 3, Serous, Clear Cell, Carcinosarcoma)

• SLN mapping represents an acceptable alternative to systematic lymphadenectomy 1, 2
• The SENTOR trial showed 96% sensitivity (95% CI: 81-100%) for detecting nodal metastases in intermediate and high-grade disease 2
• Recent meta-analysis demonstrates no difference in overall survival, disease-free survival, or recurrence rates between SLN mapping and lymphadenectomy in high-risk patients 3, 4
• Subgroup analysis actually favored SLN mapping for overall survival in high-risk populations (OR 0.62,95% CI 0.44-0.89) 3

Technical Specifications

Preferred Technique

Indocyanine green (ICG) with cervical injection is the optimal method 1, 5

• ICG provides superior bilateral detection rates compared to blue dye alone 5
• Cervical injection increases bilateral SLN detection but may decrease para-aortic detection 5
• Overall detection rate: 81% with 50% bilateral pelvic detection 2, 5

Surgical Algorithm

When performing SLN mapping, follow this protocol:

1. Inject tracer before hysterectomy (except when bulky uterus prevents vascular access)
2. If bilateral mapping successful: remove only sentinel nodes
3. If unilateral mapping failure: perform side-specific lymphadenectomy on the unmapped side 2
4. Always remove any suspicious or grossly enlarged nodes regardless of mapping results 2
5. Consider reinjection if initial mapping fails 2

Ultrastaging Protocol

All sentinel nodes should undergo ultrastaging with serial sectioning and H&E staining ± cytokeratin immunohistochemistry 2

• Ultrastaging detects micrometastases in 5-15% of patients that would be missed by standard pathology 2
• This enhanced detection leads to upstaging and altered adjuvant therapy in a significant proportion of cases
• SLN mapping with ultrastaging detects 3-fold more metastatic disease than standard lymphadenectomy (30.3% vs 14.7%, p<0.001) 2

Clinical Outcomes and Safety

Morbidity Reduction

SLN mapping significantly reduces perioperative complications compared to lymphadenectomy 6

• Complication rate: 5.9% for SLN mapping vs 7.3% for lymphadenectomy (aRR 0.85,95% CI 0.77-0.95) 6
• Patients avoid the long-term morbidity of complete lymphadenectomy including lymphedema

Oncologic Safety

• No difference in recurrence rates between SLN mapping and lymphadenectomy (HR 0.89,95% CI 0.74-1.07) 4
• No difference in mortality (HR 0.72,95% CI 0.56-1.01) 4
• 50-month recurrence-free survival of 84.7% in patients with detected SLN 2
• False-negative rate <5% when proper surgical algorithm followed 2

Important Caveats

When NOT to Perform SLN Mapping

• Apparent distant metastatic disease on imaging or surgical exploration - nodal staging will not change management 2
• Bulky or grossly positive nodes visible at surgery - proceed directly to therapeutic lymphadenectomy

Institutional Requirements

SLN mapping should only be performed at institutions with established expertise in the technique 2

• Surgeon expertise and attention to technical detail are critical for success
• Close adherence to the surgical algorithm is essential to maintain <5% false-negative rate

Management of Low-Volume Metastases

The clinical significance of isolated tumor cells (ITCs) detected by ultrastaging remains under investigation 2

• ITCs are designated as pN0(i+) and do not change overall stage per AJCC 8th edition 2
• However, 83% of patients with ITCs receive adjuvant chemotherapy in practice 2
• Three-year recurrence-free survival with ITCs is 90% 2

Current Adoption and Future Directions

SLN mapping utilization increased dramatically from 1.8% in 2012 to 35.3% in 2018, while lymphadenectomy decreased from 63.5% to 39.1% 6. Despite higher costs compared to hysterectomy alone ($10,479 vs $9,149), the reduced morbidity and improved detection of metastatic disease justify this approach 6.

The evidence strongly supports SLN mapping as the preferred lymph node staging strategy across all risk categories of endometrial cancer when performed by experienced surgeons using ICG and proper surgical algorithms.